May 15, 2019
May 30, 2019
Vancouver, British Columbia– Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines for gene and cell therapy used in oncology, rare disease and infectious disease, today announced that Dr. James Taylor, PNI’s Chief Executive Officer and Co-founder, will make a company presentation titled, "How Precision NanoSystems’ NxGen Technology Drives the Creation of Transformative Nanomedicines.” Dr. Taylor will preview PNI’s proprietary NxGen microfluidic mixer designed exclusively for nanomedicine development with > 25x throughput of existing technology. The presentation will take place on Monday, June 3 at 4:15 PM in Theater 1. NewsWire Link.
Details of the Corporate Presentation:
Date: Monday, June 3, 2019
Time: 4:15 pm ET
Location: Company Presentation Theatre 1
Session ID: 550605
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology.
About the BIO International Convention
The BIO International Convention in Philadelphia celebrates the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Attendees will take advantage of unparalleled business partnering, gain insights in hundreds of education sessions, and network with 16,000+ of biotech's most influential. Learn more at convention.bio.org.
May 15, 2019
Jun 07, 2018
Precision NanoSystems (PNI) today announced that it has closed a US$6M Series B investment. The funds will be used to expand PNI’s products and services globally and to provide a clinical manufacturing solution targeted at organizations devel...